.png){kind=logo}
PathAI, an AI healthcare business located in the United States, is revolutionizing pathology with highly advanced machine learning technologies that improve diagnostic accuracy, shorten timelines for drug development, and enable precision medicine, while simultaneously changing the clinical workflows for digital pathology and elevating the standard of care globally.
PathAI is enhancing cancer diagnostics and therapeutics through disruptive artificial intelligence technologies. Its world-class platforms are creating seamless digital pathology workflows and enabling collaboration among pathologists and biopharma innovators that lead health advances.
PathAI has raised over $255 million and is developing a CAP / CLIA laboratory in Memphis, TN to help spur a new era of precision medicine using technology and community discovery.
PathAI offers the following products and services: Translational Research, Clinical Development Services, Real-World Data, Companion Diagnostics, IHCExplore™, PathExplore™, LiverExplore™, IBDExplore™, AISight® Digital Pathology Platform, AI Product Solutions, Precision Pathology Network, BioPharma Services, AI Product Menu, and BioPharma Lab Services.
PathAI earns revenue through AI diagnostics, platform licensing, lab services, research collaborations, and strategic partnerships with leading biopharma companies.
Client Segments: Healthcare Providers, Pathology Labs, Biopharma Companies, Research Institutions
Target Companies: Large Healthcare Systems, Pharmaceutical Firms, Diagnostic Labs, Clinical Research Organizations
Target Geography: Global, including North America, Europe, Asia-Pacific, Latin America, and the Middle East
